相关实验视频

Updated: Feb 7, 2026

Preparation and In Vitro Characterization of Magnetized miR-modified Endothelial Cells
09:58

Preparation and In Vitro Characterization of Magnetized miR-modified Endothelial Cells

Published on: May 2, 2017

8.1K

在动脉样硬化中,LncRNA ZEB2-AS1调节ox-LDL诱导的血管内皮细胞功能障碍通过海绵 miR-149-5pp

Kun Zhang1, Wei Song2, Bing Liu1

  • 1Department of Vascular Surgery, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China.

Journal of biochemical and molecular toxicology
|February 5, 2026
PubMed
概括

长非编码RNAZEB2-AS1在动脉样硬化 (AS) 中被上调,通过向miR-149-5p.p.来恶化内皮功能障碍. 这表明ZEB2-AS1是潜在的生物标志物和AS的治疗标.

关键词:
在HUVECs中,粘附性 粘附性 粘附性 粘附性动脉样硬化 动脉样硬化诊断 诊断 诊断 诊断 诊断 诊断这是一种炎症炎症炎症炎症.在cRNA ZEB2 - AS1 中.

更多相关视频

Stimulation of Vascular Endothelial Cells Using Neutrophil Extracellular Traps in the Presence of Low-Density Lipoprotein07:26

Stimulation of Vascular Endothelial Cells Using Neutrophil Extracellular Traps in the Presence of Low-Density Lipoprotein

Published on: August 12, 2025

735
Inducing Myointimal Hyperplasia Versus Atherosclerosis in Mice: An Introduction of Two Valid Models08:34

Inducing Myointimal Hyperplasia Versus Atherosclerosis in Mice: An Introduction of Two Valid Models

Published on: May 14, 2014

12.6K

相关概念视频

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.0K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.7K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
430
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1.1K
Seedless Vascular Plants03:24

Seedless Vascular Plants

Seedless Vascular Plants Were the First Tall Plants on Earth
67.1K
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
547